CareDx Past Earnings Performance
Past criteria checks 0/6
CareDx's earnings have been declining at an average annual rate of -37.1%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 24.3% per year.
Key information
-37.1%
Earnings growth rate
-28.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 24.3% |
Return on equity | -72.8% |
Net Margin | -67.9% |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge
Apr 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
Mar 02CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry
Dec 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price
Jun 29Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA)
May 16CareDx: Shaking Off First-Mover Disadvantage
Oct 18CareDx: Best Near Cap-Gain Health Diagnostics Prospect Say Market Makers
Aug 08Revenue & Expenses BreakdownBeta
How CareDx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 280 | -190 | 201 | 82 |
30 Sep 23 | 297 | -91 | 202 | 87 |
30 Jun 23 | 309 | -84 | 196 | 90 |
31 Mar 23 | 320 | -81 | 198 | 93 |
31 Dec 22 | 322 | -77 | 196 | 90 |
30 Sep 22 | 319 | -74 | 193 | 89 |
30 Jun 22 | 315 | -69 | 187 | 86 |
31 Mar 22 | 308 | -50 | 170 | 82 |
31 Dec 21 | 296 | -31 | 152 | 77 |
30 Sep 21 | 276 | -18 | 136 | 68 |
30 Jun 21 | 254 | -9 | 123 | 61 |
31 Mar 21 | 221 | -14 | 112 | 55 |
31 Dec 20 | 192 | -19 | 103 | 49 |
30 Sep 20 | 169 | -20 | 93 | 45 |
30 Jun 20 | 150 | -19 | 86 | 41 |
31 Mar 20 | 139 | -20 | 81 | 35 |
31 Dec 19 | 127 | -22 | 75 | 31 |
30 Sep 19 | 115 | -21 | 68 | 26 |
30 Jun 19 | 102 | -39 | 58 | 21 |
31 Mar 19 | 88 | -45 | 51 | 17 |
31 Dec 18 | 77 | -47 | 45 | 15 |
30 Sep 18 | 66 | -75 | 39 | 14 |
30 Jun 18 | 57 | -69 | 35 | 13 |
31 Mar 18 | 51 | -59 | 31 | 12 |
31 Dec 17 | 48 | -55 | 33 | 12 |
30 Sep 17 | 47 | -39 | 32 | 10 |
30 Jun 17 | 47 | -29 | 33 | 7 |
31 Mar 17 | 46 | -35 | 34 | 4 |
31 Dec 16 | 41 | -39 | 32 | 12 |
30 Sep 16 | 36 | -29 | 29 | 0 |
30 Jun 16 | 31 | -28 | 26 | 0 |
31 Mar 16 | 27 | -21 | 22 | 0 |
31 Dec 15 | 28 | -14 | 21 | 0 |
30 Sep 15 | 29 | -9 | 19 | 0 |
30 Jun 15 | 29 | -4 | 17 | 0 |
31 Mar 15 | 29 | 0 | 16 | 0 |
31 Dec 14 | 27 | 1 | 15 | 0 |
30 Sep 14 | 25 | 0 | 13 | 0 |
30 Jun 14 | 24 | -2 | 13 | 0 |
31 Mar 14 | 23 | -3 | 11 | 0 |
31 Dec 13 | 22 | -4 | 11 | 0 |
Quality Earnings: CDNA is currently unprofitable.
Growing Profit Margin: CDNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CDNA is unprofitable, and losses have increased over the past 5 years at a rate of 37.1% per year.
Accelerating Growth: Unable to compare CDNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CDNA has a negative Return on Equity (-72.81%), as it is currently unprofitable.